Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
Ann Rheum Dis. 2013 May; 72(5):741–4
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2013 May; 72(5):741–4
Molecular Immunology 2007; 44:2497-506
Immunological Reviews 2009; 228:273-87
Best Practice & Research Clinical Rheumatology 2010; 24:513-26
Rheumatology 2013: doi: 10.1093/rheumatology/kes417
The New England Journal of Medicine 2010; 363(14):1303-12
Arthritis & Rheumatism 2011; 63(2):337-45
Arthritis & Rheumatism 2012; 64(4):970-81
Annals of Rheumatic Diseases 2013; doi:10.1136/annrheumdis-2012-202442
The Journal of Rheumatology 2013; 40(3):369-78